Current Report Filing (8-k)
November 12 2020 - 7:11AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(D)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): November 12, 2020
Leap Therapeutics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-37990
|
27-4412575
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
47
Thorndike Street, Suite B1-1
Cambridge, MA
|
02141
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (617) 714-0360
N/A
(Former name or former
address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001
|
LPTX
|
Nasdaq Global Market
|
Item 2.02. Results of Operations and Financial
Condition
On November 12, 2020, Leap Therapeutics,
Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2020. The full text
of the press release issued by the Company in connection with the announcement is furnished as Exhibit 99.1 to this Current Report
on Form 8-K.
The information contained herein and in
the accompanying exhibit shall not be incorporated by reference into any filing of the Company, whether made before or after the
date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference
to such filing. The information in this Current Report on Form 8-K, including the information set forth under this Item 2.02 and
the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
LEAP THERAPEUTICS, INC.
|
|
|
Dated: November 12, 2020
|
By:
|
/s/ Douglas E. Onsi
|
|
Name:
|
Douglas E. Onsi
|
|
Title:
|
Chief Executive Officer and President
|
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Sep 2023 to Sep 2024